Log in

NeutriSci International Stock Forecast, Price & News

-0.01 (-7.41 %)
(As of 10/23/2020 03:58 PM ET)
Today's Range
Now: C$0.13
50-Day Range
MA: C$0.13
52-Week Range
Now: C$0.13
Volume523,089 shs
Average Volume312,033 shs
Market CapitalizationC$18.67 million
P/E RatioN/A
Dividend YieldN/A
NeutriSci International Inc. develops and markets nutraceutical products in Canada and internationally. It offers Neuenergy, a chewable tablet designed to deliver enhanced focus and mental clarity; nu.thc and nu.cbd sugar-free chewable cannabinoid tablets that offer a metered dose of THC/CBD; and BluScience line of products to support optimal health. The company markets its products through retail and online channels. NeutriSci International Inc. is headquartered in Calgary, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.50 out of 5 stars

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic



Sales & Book Value

Annual SalesC$45,251.00
Cash FlowC$0.00 per share
Book ValueC$0.00 per share



Market CapC$18.67 million
Next Earnings Date12/4/2020 (Estimated)
OptionableNot Optionable
-0.01 (-7.41 %)
(As of 10/23/2020 03:58 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NU News and Ratings via Email

Sign-up to receive the latest news and ratings for NU and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

NeutriSci International (CVE:NU) Frequently Asked Questions

How has NeutriSci International's stock been impacted by COVID-19 (Coronavirus)?

NeutriSci International's stock was trading at C$0.04 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, NU stock has increased by 212.5% and is now trading at C$0.13.
View which stocks have been most impacted by COVID-19

When is NeutriSci International's next earnings date?

NeutriSci International is scheduled to release its next quarterly earnings announcement on Friday, December 4th 2020.
View our earnings forecast for NeutriSci International

Who are some of NeutriSci International's key competitors?

What other stocks do shareholders of NeutriSci International own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeutriSci International investors own include Aurora Cannabis (ACB), Emcor Group (EME), Incyte (INCY), Northwest Pipe (NWPX), UnitedHealth Group (UNH), Watsco (WSO), Zimmer Biomet (ZBH), 3i Infrastructure (3IN), Axos Financial (AX) and Actinium Pharmaceuticals (ATNM).

Who are NeutriSci International's key executives?

NeutriSci International's management team includes the following people:
  • Mr. Glen Rehman, CEO, Pres & Director
  • Mr. John Robert Chisholm, Chief Financial Officer (Age 57)
  • Mr. Thierry Sorhaitz, VP of Sales & Marketing

What is NeutriSci International's stock symbol?

NeutriSci International trades on the Canadian Venture Exchange (CVE) under the ticker symbol "NU."

How do I buy shares of NeutriSci International?

Shares of NU and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is NeutriSci International's stock price today?

One share of NU stock can currently be purchased for approximately C$0.13.

How big of a company is NeutriSci International?

NeutriSci International has a market capitalization of C$18.67 million and generates C$45,251.00 in revenue each year.

What is NeutriSci International's official website?

The official website for NeutriSci International is www.neutrisci.com.

How can I contact NeutriSci International?

The company can be reached via phone at 403-264-6320.

This page was last updated on 10/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.